Samsung Biologics Partners with Kurma for Biologics Development and Manufacturing

Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.

Samsung Biologics will provide CMC (chemistry, manufacturing, and control) services to streamline the gene-to-IND (investigational new drug) process for Kurma Partners' portfolio companies, accelerating clinical development with its advanced facilities and expertise.

John Rim, President and CEO of Samsung Biologics commented, “With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients.”

“We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market.” said Daniel Parera, Partner at Kurma Partners. 

This agreement highlights Samsung Biologics' eagerness to work with emerging biotech firms in drug development and manufacturing while expanding its presence in key sectors in the U.S. and European markets.

Samsung Biologics and Kurma Partners announce strategic partnership for...
Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma’s portfolio companies. © Samsung Biologics

Company

Kurma Partners

24 rue Royale, 5e etage
75008 Paris
France

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.